Back to dashboard
CommercialCoverageMedium impact

08.01.35j, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)

Independence Blue Cross·Oncology, Hematology, Pediatrics·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Insurance policy updated medical necessity criteria for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®), a specialized cancer medication. This affects coverage requirements and approval processes for this specific drug used in cancer treatment.

Action Required

Action needed
By August 25, 2025: Billing team must review updated medical necessity criteria for Rylaze® (Asparaginase Erwinia Chrysanthemi). Update prior authorization workflows and ensure providers document required medical necessity criteria before prescribing. Review full policy at medpolicy.ibx.com for specific documentation requirements.

Related policy hubs